Patent application number | Description | Published |
20110257305 | REDISPERSIBLE POLYMER POWDERS PREPARED FROM LOW CARBOXYLATION STYRENE BUTADIENE-BASED LATEX - A water redispersible polymer powder is produced by drying an aqueous mixture of a low carboxylation, low Tg, large average particle size water insoluble film-forming polymer latex or emulsion and a colloidal stabilizer. The latex polymer may have an average particle size of 2000 Å to 5,000 Å, and an amount of carboxylation of 0.1% to 2.75% by weight of at least one ethylenically unsaturated dicarboxylic acid, salts or mixtures thereof, based upon the weight of the polymer. Dispersions containing the polymer and a polyvinyl alcohol as a colloidal stabilizer exhibit an unexpectedly low viscosity which facilitates spray drying and permits use of high solids content dispersions with low pressure spray drying to increase production efficiency. Cement compositions such as mortars, which contain the redispersible polymer powder exhibit unexpectedly lower rates of viscosity buildup for better workability or troweling, faster set time, and superior heat flow characteristics. | 10-20-2011 |
20120318434 | CEMENTITIOUS TILE ADHESIVES AND METHOD OF APPLYING THE SAME TO A TILE SUBSTRATE - Cement tile adhesives and methods for using them, the adhesives comprising a dry mix of a water-redispersible polymer powder made from a low carboxylation, large particle size water-soluble film-forming vinyl aromatic-diene copolymer latex and a reduced amount of cellulose ether exhibit superior water immersion shear strength and freeze/thaw shear strength. | 12-20-2012 |
20150087751 | DRY MIX FORMULATIONS CONTAINING CARBOXYLATED STYRENE-BUTADIENE REDISPERSIBLE POLYMER POWDERS AND ALUMINA RICH CONTAINING CEMENTS - Dry mix formulations containing a redispersible polymer powder (RDP) made of a low carboxylation, large particle size water-insoluble film—forming styrene butadiene polymer having at least one ethylenically unsaturated dicarboxylic acid monomer, and a high alumina content cement such as a calcium aluminate cement (CAC) or a calcium sulfoaluminate cement (CSA) provides cement compositions having unexpectedly superior water immersion shear strength and set time for a cement containing tile adhesive (CBTA or CTA), superior adhesion properties in water proofing mortars or mortar applications, and superior flexural and compressive strength in grout applications. | 03-26-2015 |
Patent application number | Description | Published |
20080206140 | Cspcna Isoform Antibodies and Uses Thereof - Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed. | 08-28-2008 |
20080220540 | Method for purifying cancer-specific proliferating cell nuclear antigen - The method for developing an antibody that exclusively binds to csPCNA. | 09-11-2008 |
20090061432 | CSPCNA ISOFORM MODIFICATIONS AND USES THEREOF - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 03-05-2009 |
20090232882 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 09-17-2009 |
20100240874 | METHOD FOR PURIFYING CANCER-SPECIFIC PROLIFERATING CELL NUCLEAR ANTIGEN - An isolated antibody that binds a cancer specific Proliferating Cell Nuclear Antigen (csPCNA) that binds to the amino acid sequence LeuLysGlnLeuAspAlaGlnGlnThrGlnLeuArgIle AspSerPhePheArgLeuAlaGlnGlnGluLysGluAspAlaLysArg (SEQ ID No. 1). An immunoassay that utilizes an isolated antibody that binds a form of csPCNA that binds to the SEQ ID No. 1 to identify the presence of csPCNA in a sample. | 09-23-2010 |
20110076342 | CANCER PEPTIDE THERAPEUTICS - Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics. | 03-31-2011 |
20110195510 | csPCNA Isoform Modifications And Uses Thereof - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 08-11-2011 |
20120195978 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 08-02-2012 |
20120258482 | PCNA METHYLTRANSFERASE - Proliferating cell nuclear antigen (PCNA)-dependent glutamate methyltransferases are disclosed that can methylesterify one or more glutamic acid or aspartic acid residues of PCNA. | 10-11-2012 |
20140212510 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 07-31-2014 |
Patent application number | Description | Published |
20120244076 | csPCNA Isoform Antibodies And Uses Thereof - Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed. | 09-27-2012 |
20130345231 | ANTICANCER THERAPEUTIC AGENTS - The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy. | 12-26-2013 |
20140296156 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 10-02-2014 |
20150259407 | csPCNA Isoform Antibodies And Uses Thereof - Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed. | 09-17-2015 |